Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Background-Use of surgery for the treatment of infective endocarditis (IE) as related to surgical indications and operative risk for mortality has not been well defined. Methods and Results-The International Collaboration on Endocarditis-PLUS (ICE-PLUS) is a prospective cohort of consecutively enrolled patients with definite IE from 29 centers in 16 countries. We included patients from ICE-PLUS with definite left-sided, non-cardiac device-related IE who were enrolled between September 1, 2008, and December 31, 2012. A total of 1296 patients with left-sided IE were included. Surgical treatment was performed in 57% of the overall cohort and in 76% of patients with a surgical indication. Reasons for nonsurgical treatment included poor prognosis (33.7%), hemodynamic instability (19.8%), death before surgery (23.3%), stroke (22.7%), and sepsis (21%). Among patients with a surgical indication, surgical treatment was independently associated with the presence of severe aortic regurgitation, abscess, embolization before surgical treatment, and transfer from an outside hospital. Variables associated with nonsurgical treatment were a history of moderate/severe liver disease, stroke before surgical decision, and Staphyloccus aureus etiology. The integration of surgical indication, Society of Thoracic Surgeons IE score, and use of surgery was associated with 6-month survival in IE. Conclusions-Surgical decision making in IE is largely consistent with established guidelines, although nearly one quarter of patients with surgical indications do not undergo surgery. Operative risk assessment by Society of Thoracic Surgeons IE score provides prognostic information for survival beyond the operative period. S aureus IE was significantly associated with nonsurgical management.
Association between surgical indications, operative risk, and clinical outcome in infective endocarditis a prospective study from the international collaboration on endocarditis
Chu V. H.;Park L. P.;Athan E.;Delahaye F.;Freiberger T.;Lamas C.;Miro J. M.;Mudrick D. W.;Strahilevitz J.;Tribouilloy C.;Durante-Mangoni E.;Pericas J. M.;Fernandez-Hidalgo N.;Nacinovich F.;Rizk H.;Krajinovic V.;Giannitsioti E.;Hurley J. P.;Hannan M. M.;Wang A.;Clara L.;Sanchez M.;Casabe J.;Cortes C.;Oses P. F.;Ronderos R.;Sucari A.;Thierer J.;Altclas J.;Kogan S.;Spelman D.;Harris O.;Kennedy K.;Tan R.;Gordon D.;Korman T.;Kotsanas D.;Dever R.;Jones P.;Konecny P.;Lawrence R.;Rees D.;Ryan S.;Feneley M. P.;Harkness J.;Post J.;Reinbott P.;Gattringer R.;Wiesbauer F.;Andrade A. R.;de Brito A. C. P.;Guimaraes A. C.;Grinberg M.;Mansur A. J.;Siciliano R. F.;Strabelli T. M. V.;Vieira M. L. C.;de Medeiros Tranchesi R. A.;Paiva M. G.;Fortes C. Q.;de Oliveira Ramos A.;Ferraiuoli G.;Golebiovski W.;Weksler C.;Karlowsky J. A.;Keynan Y.;Morris A. M.;Rubinstein E.;Jones S. B.;Garcia P.;Cereceda M.;Fica A.;Fernandez R.;Franco L.;Gonzalez J.;Jaramillo A. N.;Barsic B.;Bukovski S.;Rudez I.;Vincelj J.;Pol J.;Malisova B.;Ashour Z.;El Kholy A.;Mishaal M.;Osama D.;Aissa N.;Alauzet C.;Alla F.;Campagnac C.;Doco-Lecompte T.;Selton-Suty C.;Casalta J. -P.;Fournier P. -E.;Habib G.;Raoult D.;Thuny F.;Delahaye A.;Vandenesch F.;Donal E.;Donnio P. Y.;Flecher E.;Michelet C.;Revest M.;Tattevin P.;Chevalier F.;Jeu A.;Remadi J. P.;Rusinaru D.;Bernard Y.;Chirouze C.;Hoen B.;Leroy J.;Plesiat P.;Naber C.;Neuerburg C.;Mazaheri B.;Athanasia S.;Giamarellou H.;Thomas T.;Mylona E.;Paniara O.;Papanicolaou K.;Pyros J.;Skoutelis A.;Papanikolaou K.;Sharma G.;Francis J.;Nair L.;Thomas V.;Venugopal K.;Cahan A.;Gilon D.;Israel S.;Korem M.;Mattucci I.;Pinto D.;Agrusta F.;Senese A.;Ragone E.;Utili R.;Cecchi E.;De Rosa F.;Forno D.;Imazio M.;Trinchero R.;Grossi P.;Lattanzio M.;Toniolo A.;Goglio A.;Raglio A.;Ravasio V.;Rizzi M.;Suter F.;Carosi G.;Magri S.;Signorini L.;Kanafani Z.;Kanj S. S.;Sharif-Yakan A.;Abidin I.;Tamin S. S.;Martinez E. R.;Nieto G. I. S.;van der Meer J. T. M.;Chambers S.;Holland D.;Morris A.;Raymond N.;Read K.;Murdoch D. R.;Dragulescu S.;Ionac A.;Mornos C.;Butkevich O. M.;Chipigina N.;Kirill O.;Vadim K.;Vinogradova T.;Edathodu J.;Halim M.;Liew Y. Y.;Tan R. -S.;Lejko-Zupanc T.;Logar M.;Mueller-Premru M.;Commerford P.;Commerford A.;Deetlefs E.;Hansa C.;Ntsekhe M.;Almela M.;Armero Y.;Azqueta M.;Castaneda X.;Cervera C.;Falces C.;Garcia-dela-Maria C.;Fita G.;Gatell J. M.;Heras M.;Llopis J.;Marco F.;Mestres C. A.;Miro J. M.;Moreno A.;Ninot S.;Pare C.;Ramirez J.;Rovira I.;Sitges M.;Anguera I.;Font B.;Guma J. R.;Bermejo J.;Bouza E.;Fernandez M. A. G.;Gonzalez-Ramallo V.;Marin M.;Munoz P.;Pedromingo M.;Roda J.;Rodriguez-Creixems M.;Solis J.;Almirante B.;Tornos P.;de Alarcon A.;Parra R.;Alestig E.;Johansson M.;Olaison L.;Snygg-Martin U.;Pachirat O.;Pachirat P.;Pussadhamma B.;Senthong V.;Casey A.;Elliott T.;Lambert P.;Watkin R.;Eyton C.;Klein J. L.;Bradley S.;Kauffman C.;Bedimo R.;Corey G. R.;Crowley A. L.;Douglas P.;Drew L.;Fowler V. G.;Holland T.;Lalani T.;Samad Z.;Sexton D. J.;Stryjewski M.;Woods C. W.;Lerakis S.;Cantey R.;Steed L.;Wray D.;Dickerman S. A.;Bonilla H.;DiPersio J.;Salstrom S. -J.;Baddley J.;Patel M.;Peterson G.;Stancoven A.;Levine D.;Riddle J.;Rybak M.;Cabell C. H.;Baloch K.;Dixon C. C.;Harding T.;Jones-Richmond M.;Sanderford B.;Stafford J.;Anstrom K.;Bayer A. S.;Karchmer A. W.;Durack D. T.;Eykyn S.;Moreillon P.
2015-01-01
Abstract
Background-Use of surgery for the treatment of infective endocarditis (IE) as related to surgical indications and operative risk for mortality has not been well defined. Methods and Results-The International Collaboration on Endocarditis-PLUS (ICE-PLUS) is a prospective cohort of consecutively enrolled patients with definite IE from 29 centers in 16 countries. We included patients from ICE-PLUS with definite left-sided, non-cardiac device-related IE who were enrolled between September 1, 2008, and December 31, 2012. A total of 1296 patients with left-sided IE were included. Surgical treatment was performed in 57% of the overall cohort and in 76% of patients with a surgical indication. Reasons for nonsurgical treatment included poor prognosis (33.7%), hemodynamic instability (19.8%), death before surgery (23.3%), stroke (22.7%), and sepsis (21%). Among patients with a surgical indication, surgical treatment was independently associated with the presence of severe aortic regurgitation, abscess, embolization before surgical treatment, and transfer from an outside hospital. Variables associated with nonsurgical treatment were a history of moderate/severe liver disease, stroke before surgical decision, and Staphyloccus aureus etiology. The integration of surgical indication, Society of Thoracic Surgeons IE score, and use of surgery was associated with 6-month survival in IE. Conclusions-Surgical decision making in IE is largely consistent with established guidelines, although nearly one quarter of patients with surgical indications do not undergo surgery. Operative risk assessment by Society of Thoracic Surgeons IE score provides prognostic information for survival beyond the operative period. S aureus IE was significantly associated with nonsurgical management.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11390/1327178
Citazioni
ND
254
ND
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.